Neurocrine Biosciences | Bienes



Assets Cambio Fecha
AbbVie USD 135.16B 8.26B 2024-12
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
Agios Pharmaceuticals USD 1.56B 107.68M 2025-03
ALKERMES USD 2.08B 26.41M 2025-03
Alnylam Pharmaceuticals USD 4.21B 26.17M 2025-03
Amgen USD 89.37B 2.47B 2025-03
Biogen USD 28.03B 16.2M 2025-03
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Cytokinetics USD 1.4B 34.39M 2024-12
Dynavax Technologies USD 986.26M 75.73M 2024-12
Exelixis USD 2.95B 12.59M 2025-01
Gilead Sciences USD 56.43B 2.56B 2025-03
Halozyme Therapeutics USD 2.06B 54.55M 2024-12
Incyte USD 5.75B 305.04M 2025-03
Ionis Pharmaceuticals USD 2.81B 190.73M 2025-03
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Prothena USD 547.11M 48.15M 2024-12
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Repligen USD 2.85B 22.48M 2025-03
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
Teva Pharmaceutical Industries USD 39.33B 2.43B 2024-12
Ultragenyx Pharmaceutical USD 1.5B 34.91M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Neurocrine Biosciences Bienes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.